Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial - Weber, J S; D’Angelo, S P; Minor, D; Hodi, F S; Gutzmer, R; Neyns, B; Hoeller, C; Khushalani, N I; Miller, W H; Lao, C D; Linette, G P; Thomas, L; Lorigan, P; Grossmann, K F; Hassel, J C; Maio, M; Sznol, M; Ascierto, P A; Mohr, P; Chmielowski, B; Bryce, A; Svane, I M; Grob, J-J; Krackhardt, A M; Horak, C; Lambert, A; Yang, A S; Larkin, J (Lancet Oncol, 2015)